The Pascoal MOCUMBI Award, established by the EDCTP (Europe-Developing Countries Partnership for Clinical Trials), is awarded every two years to an outstanding African or European personality who has made significant advances in the field of health research. In addition to its scientific excellence, the laureate must have made a significant contribution to the EDCTP’s goals of building the capacity of researchers for quality clinical research in Africa and supporting South-South and North-South networks.

This prestigious award is named after Dr. Pascoal MOCUMBI Mozambican pediatrician doctor,
former first High Representative of the EDCTP and former Prime Minister of Mozambique.

Dr MOCUMBI has made outstanding contributions to the promotion of health research partnerships and supported capacity building in Africa.
The prize was awarded Monday, September 17, 2018 to Professor Souleymane MBOUP in Lisbon by Dr. Leonardo Santos Simao former Minister of Foreign Affairs of Mozambique in the presence of Professor Marcel TANNER Director of the Institute of Tropical Medicine Switzerland and President of the Academy of Sciences Switzerland and Dr Michael MAKANGA, Executive Director of EDCTP.

“I am deeply honored and grateful to receive this award. Dr. MOCUMBI has had a special place in the history of medical research in Africa and has been in many ways the pioneer of what we call Global Health”, humbly declared Professor MBOUP.

“Although we have collectively achieved many successes, infectious diseases are far from being under control, especially in sub-Saharan Africa.

New pathogens will continue to appear and together we will have to prepare for many new challenges. ”
As a reminder, Professor Souleymane MBOUP, co-discoverer of the second acquired immunodeficiency syndrome virus (HIV / AIDS) is also the designer of the Institute for Health Research, Epidemiological Surveillance and Training (IRESSEF). EDCTP funds clinical research to accelerate the development of new drugs, vaccines, microbicides and diagnostic tools to improve the fight against HIV / AIDS, tuberculosis and malaria as well as other infectious diseases related to poverty in Africa. Africa, with a focus on Phase II and III clinical trials.